NovoCure Limited announced on November 9, 2026 that the FDA issued a Not Approvable Letter for Optune Mya, citing uncertainty about clinical benefit but no safety concerns. It plans to discuss approval options that would not require additional clinical studies.
NVCR · NovoCure Ltd
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $10.69
- Open
- $10.85
- Day range
- $10.54–11.11
- 52-week closing range
- $10.03–19.99
- Average volume, 30 days
- 1.8M
- Short interest
- 12.9M · 11.0% of shares · 6.0 days
- Short volume, last session
- 47%
- Last earnings
- Oct 29, 2026
- Latest filing
- 10-Q · Oct 29
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Novocure reported record third-quarter net revenue of $193 million, up 16% year-over-year, with adjusted EBITDA of positive $16 million compared with negative $3 million a year earlier. It raised 2026 net revenue guidance to $736 to $743 million and adjusted EBITDA guidance to $24 to $34 million. Optune Pax ended the quarter with 276 active patients and $3.7 million in net revenue as U.S. momentum slowed.
Novocure reported third-quarter 2026 net revenues of $193.4 million, up 16% from the same period in 2025. Full-year 2026 net revenue guidance was raised to $736 million - $743 million, and adjusted EBITDA guidance to $24 million - $34 million. Japan's Ministry of Health, Labour and Welfare approved Optune Pax for locally advanced pancreatic cancer in October 2026.
Net revenues rose 16% to $193.4 million for the three months ended September 30, 2026. The net loss narrowed to $10.4 million, and a non-cash $43.4 million expense tied to cancelled PSUs was recorded in general and administrative costs. Cash, cash equivalents and short-term investments totaled $463.5 million, which the company believes is sufficient for at least the next 12 months.
Japan’s Ministry of Health, Labour and Welfare approved Novocure’s Optune Pax for adult patients with unresectable locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 29, 2026TL;DR. Q3 net revenue rose 16% to $193.4 million on 19% active-patient growth, gross margin expanded to 77%, profitability improved sharply, and Novocure raised its 2026 revenue and adjusted EBITDA guidance. Japan expanded through Optune Pax approval and Optune Lua growth, while Maya and KEYNOTE D58 remain on track for Q4 2026 milestones; the U.S. Optune Pax launch continued to face significant access and share-of-voice challenges.
- + Q3 net revenue increased 16% to $193.4 million, driven primarily by 19% global active-patient growth.
- + Gross margin expanded to 77% from 73%, and management expects a mid-to-high 70s margin through Q4 2026.
- − Foreign exchange rates reduced quarterly revenue by $2 million.
- − Novocure remained unprofitable, reporting a Q3 net loss of $10.4 million and a loss per share of $0.09.
- − R&D and clinical-study expenses increased 8% to $58.1 million, primarily because of KEYNOTE D58.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $10.76M | Three months ended June 30, 2026 filing | — |
| Cost of revenues per active patient per month | $2,483 | Three months ended June 30, 2026 filing | — |
| Prescriptions received in period - United States | 418 | Three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVCR
this stock
NovoCure Ltd
|
$1.25B | -17.3% | +8.3% | — | 11.0% |
|
ABT
Abbott Laboratories
|
$179.90B | -17.1% | +5.7% | 38.8 | 1.1% |
|
MDT
Medtronic plc
|
$128.69B | +4.7% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$119.19B | -10.9% | +11.2% | 33.3 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.31B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 27
NovoCure Limited announced on November 9, 2026 that the FDA issued a Not Approvable Letter for Optune Mya, citing uncertainty about clinical benefit but no safety concerns. It plans to discuss approval options that would not require additional clinical studies.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVCR | -8.8% | -29.2% | -35.5% | -18.7% | -17.3% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -3.3% | -22.9% | -29.8% | -13.4% | -22.3% |